Published in Arthritis Res Ther on July 28, 2011
RANKL synthesized by articular chondrocytes contributes to juxta-articular bone loss in chronic arthritis. Arthritis Res Ther (2012) 1.59
Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nat Commun (2015) 1.50
An HLA-DRB1-coded signal transduction ligand facilitates inflammatory arthritis: a new mechanism of autoimmunity. J Immunol (2012) 1.48
Ligation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis. J Immunol (2014) 1.44
Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res Ther (2011) 1.33
The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2012) 1.02
C/EBPα regulates osteoclast lineage commitment. Proc Natl Acad Sci U S A (2013) 0.99
Neutrophils, IL-1β, and gout: is there a link? Semin Immunopathol (2013) 0.98
IL-17 in the rheumatologist's line of sight. Biomed Res Int (2013) 0.95
Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway. Evid Based Complement Alternat Med (2013) 0.93
Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways. PLoS One (2013) 0.91
Microarray-based gene expression profiling reveals the mediators and pathways involved in the anti-arthritic activity of Celastrus-derived Celastrol. Int Immunopharmacol (2012) 0.91
Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest (2013) 0.88
Role of Micro RNAs in the Pathogenesis of Rheumatoid Arthritis: Novel Perspectives Based on Review of the Literature. Medicine (Baltimore) (2015) 0.86
Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells. Mol Carcinog (2012) 0.85
T cells as key players for bone destruction in gouty arthritis? Arthritis Res Ther (2011) 0.83
Bone and the innate immune system. Curr Osteoporos Rep (2014) 0.83
Induction of osteoclast progenitors in inflammatory conditions: key to bone destruction in arthritis. Int Orthop (2014) 0.82
Differential arthritogenicity of Staphylococcus aureus strains isolated from biological samples. BMC Infect Dis (2013) 0.81
Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int (2014) 0.80
Double-edged-sword effect of IL-1β on the osteogenesis of periodontal ligament stem cells via crosstalk between the NF-κB, MAPK and BMP/Smad signaling pathways. Cell Death Dis (2016) 0.79
IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis. Osteoporos Int (2013) 0.79
Ac45 silencing mediated by AAV-sh-Ac45-RNAi prevents both bone loss and inflammation caused by periodontitis. J Clin Periodontol (2015) 0.79
Cellular and molecular pathways of structural damage in rheumatoid arthritis. Semin Immunopathol (2017) 0.79
Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. Arch Immunol Ther Exp (Warsz) (2015) 0.78
Bone research in 2012: the ups and downs of bone in health and rheumatic disease. Nat Rev Rheumatol (2013) 0.78
Elevation of serum tumor necrosis factor α in patients with periprosthetic osteolysis: a case-control study. Clin Orthop Relat Res (2014) 0.78
Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. Clin Med Insights Reprod Health (2012) 0.78
Prolactin blocks the expression of receptor activator of nuclear factor κB ligand and reduces osteoclastogenesis and bone loss in murine inflammatory arthritis. Arthritis Res Ther (2017) 0.78
IL-1R/TLR2 through MyD88 Divergently Modulates Osteoclastogenesis through Regulation of Nuclear Factor of Activated T Cells c1 (NFATc1) and B Lymphocyte-induced Maturation Protein-1 (Blimp1). J Biol Chem (2015) 0.76
Mediators of inflammation and bone remodeling in rheumatic disease. Semin Cell Dev Biol (2015) 0.76
Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation. J Transl Med (2015) 0.76
Mucosal Langerhans Cells Promote Differentiation of Th17 Cells in a Murine Model of Periodontitis but Are Not Required for Porphyromonas gingivalis-Driven Alveolar Bone Destruction. J Immunol (2016) 0.75
Targeting BCL2 family in human myeloid dendritic cells: a challenge to cure diseases with chronic inflammations associated with bone loss. Clin Dev Immunol (2013) 0.75
Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis. Arthritis Res Ther (2016) 0.75
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis. Clin Rheumatol (2017) 0.75
Inhibition of P2X4 suppresses joint inflammation and damage in collagen-induced arthritis. Inflammation (2014) 0.75
Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats. Pharmacol Res Perspect (2015) 0.75
Rhinacanthin C Inhibits Osteoclast Differentiation and Bone Resorption: Roles of TRAF6/TAK1/MAPKs/NF-κB/NFATc1 Signaling. PLoS One (2015) 0.75
Increased chemotaxis and activity of circulatory myeloid progenitor cells may contribute to enhanced osteoclastogenesis and bone loss in the C57BL/6 mouse model of collagen-induced arthritis. Clin Exp Immunol (2016) 0.75
Allium cepa L. and Quercetin Inhibit RANKL/Porphyromonas gingivalis LPS-Induced Osteoclastogenesis by Downregulating NF-κB Signaling Pathway. Evid Based Complement Alternat Med (2015) 0.75
Role of LIGHT in the pathogenesis of joint destruction in rheumatoid arthritis. World J Exp Med (2017) 0.75
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care. PLoS One (2017) 0.75
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005) 14.95
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (1999) 12.32
Bone resorption by osteoclasts. Science (2000) 11.68
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med (1996) 8.59
Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J (1991) 8.31
Genetic regulation of osteoclast development and function. Nat Rev Genet (2003) 7.94
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell (2005) 7.64
LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature (2001) 7.44
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev (1999) 6.93
Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum (1999) 6.39
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol (2007) 5.86
RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85
IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol (1998) 5.79
Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med (1997) 5.72
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2006) 5.08
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci U S A (1990) 5.05
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
TNF-mediated inflammatory disease. J Pathol (2008) 5.00
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature (2004) 4.92
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum (1988) 4.60
High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol (2000) 4.58
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 4.58
The molecular understanding of osteoclast differentiation. Bone (2006) 4.39
Bone and haematopoietic defects in mice lacking c-fos. Nature (1993) 4.07
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med (2000) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum (2008) 4.02
Generalised bone loss in patients with early rheumatoid arthritis. Lancet (1994) 3.93
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (2008) 3.83
Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J (1994) 3.60
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
The interleukin-1 family: 10 years of discovery. FASEB J (1994) 3.38
Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med (1998) 3.20
The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A (2004) 3.15
IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 2.99
Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med (2002) 2.98
The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 2.90
Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem (2000) 2.80
Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell (1992) 2.78
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun (1998) 2.66
Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol (2010) 2.64
Interleukin-1 (IL-1) pathway. Sci Signal (2010) 2.58
The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther (2004) 2.54
Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest (1993) 2.52
Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A (1998) 2.37
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest (2004) 2.31
Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol (2005) 2.26
NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem (2007) 2.22
Tumor necrosis factor-alpha: molecular and cellular mechanisms in skeletal pathology. Gene (2003) 2.22
I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med (2005) 2.21
The IkappaB function of NF-kappaB2 p100 controls stimulated osteoclastogenesis. J Exp Med (2003) 2.20
The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 2.17
IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther (2004) 2.17
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun (2000) 2.14
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell (2008) 2.13
Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem (2001) 2.13
PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest (2006) 2.11
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res (1999) 2.06
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 2.03
Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis. Arthritis Rheum (1998) 2.01
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci (2002) 1.99
Regulation of osteoclast differentiation and function by the CaMK-CREB pathway. Nat Med (2006) 1.93
Risk of vertebral fracture in women with rheumatoid arthritis. BMJ (1993) 1.87
Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J Cell Biol (2004) 1.77
Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood (2000) 1.74
Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum (2002) 1.72
A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-independent manner. Arthritis Rheum (2009) 1.70
Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum (2000) 1.65
M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest (2005) 1.64
TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci U S A (2007) 1.61
The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, and oncostatin M in rheumatoid arthritis. Arthritis Rheum (1997) 1.60
Annotating genes with potential roles in the immune system: six new members of the IL-1 family. Trends Immunol (2001) 1.59
Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice. Arthritis Rheum (1999) 1.57
A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med (2002) 1.57
Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem (2003) 1.53
Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today (1998) 1.53
Macrophage colony-stimulating factor promotes cell survival through Akt/protein kinase B. J Biol Chem (1999) 1.51
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood (2004) 1.50
Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. Arthritis Res (2000) 1.50
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Control of RANKL gene expression. Bone (2009) 1.47
T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res (2001) 1.43
Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum (2006) 1.42
Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res (2002) 1.41
Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum (2009) 1.40
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum (2007) 3.02
Regulatory T cells protect from local and systemic bone destruction in arthritis. J Immunol (2010) 2.70
Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis. Nat Commun (2012) 2.65
Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) (2009) 2.14
Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum (2007) 2.12
High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med (2006) 2.09
Relations of vitamin D status, gender and type 2 diabetes in middle-aged Caucasians. Acta Diabetol (2014) 2.07
Platelet-derived serotonin links vascular disease and tissue fibrosis. J Exp Med (2011) 2.05
Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann Rheum Dis (2012) 1.81
How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum (2008) 1.74
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis (2010) 1.67
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum (2009) 1.65
Blockade of the hedgehog pathway inhibits osteophyte formation in arthritis. Ann Rheum Dis (2012) 1.58
Pachydermodactyly: a review. Curr Rheumatol Rep (2014) 1.56
Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis. Ann Rheum Dis (2011) 1.56
Mechanisms of Disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol (2005) 1.55
The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol (2008) 1.52
Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum (2009) 1.40
Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum (2009) 1.36
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J (2008) 1.33
Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum (2003) 1.31
12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol (2009) 1.27
Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol (2004) 1.24
Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum (2007) 1.23
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 1.21
Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum (2008) 1.20
IgG4 immune response in Churg-Strauss syndrome. Ann Rheum Dis (2011) 1.18
Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care (2012) 1.17
IgG4- related disease: an orphan disease with many faces. Orphanet J Rare Dis (2014) 1.17
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. Curr Opin Rheumatol (2014) 1.16
Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum (2008) 1.16
Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. Arthritis Rheum (2010) 1.14
CD44 is a determinant of inflammatory bone loss. J Exp Med (2005) 1.10
Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res (2004) 1.09
WNT5A is induced by inflammatory mediators in bone marrow stromal cells and regulates cytokine and chemokine production. J Bone Miner Res (2012) 1.08
Inhibition of glycogen synthase kinase 3β induces dermal fibrosis by activation of the canonical Wnt pathway. Ann Rheum Dis (2011) 1.07
The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol (2009) 1.06
Vascular cell adhesion molecule 1 as a predictor of severe osteoarthritis of the hip and knee joints. Arthritis Rheum (2009) 1.05
Churg-Strauss syndrome: update on pathophysiology and treatment. Curr Opin Rheumatol (2012) 1.02
Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther (2005) 1.01
In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood (2010) 0.98
Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol (2012) 0.97
Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum (2012) 0.96
Combining functional magnetic resonance imaging with mouse genomics: new options in pain research. Neuroreport (2010) 0.96
Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol (2013) 0.96
CCL17/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum (2010) 0.95
B-cell infiltrates induce endosteal bone formation in inflammatory arthritis. J Bone Miner Res (2008) 0.95
Microparticles stimulate angiogenesis by inducing ELR(+) CXC-chemokines in synovial fibroblasts. J Cell Mol Med (2011) 0.95
The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum (2009) 0.95
Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. Arthritis Rheum (2011) 0.94
The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum (2010) 0.94
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis (2011) 0.93
Mortality after hip fracture in Austria 2008-2011. Calcif Tissue Int (2014) 0.92
The Relapsing Polychondritis Disease Activity Index: development of a disease activity score for relapsing polychondritis. Autoimmun Rev (2012) 0.92
Anti IL-17A therapy inhibits bone loss in TNF-α-mediated murine arthritis by modulation of the T-cell balance. Eur J Immunol (2011) 0.92
Vitamin D receptor regulates TNF-mediated arthritis. Ann Rheum Dis (2011) 0.91
Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects. Clin Rev Allergy Immunol (2005) 0.90
NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. Proc Natl Acad Sci U S A (2013) 0.90
Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum (2008) 0.90
Low bone mineral density and fragility fractures in permanent vegetative state patients. J Bone Miner Res (2014) 0.89
The lonely death: chondrocyte apoptosis in TNF-induced arthritis. Autoimmunity (2007) 0.89
Successful remission induction with a combination therapy of rituximab, cyclophosphamide, and steroids in a patient with refractory optic neuritis in Wegener's granulomatosis. Clin Rheumatol (2010) 0.88
Overexpression of tumor necrosis factor causes bilateral sacroiliitis. Arthritis Rheum (2004) 0.88
Effects of p38 mitogen-activated protein kinase inhibition on anti-neutrophil cytoplasmic autoantibody pathogenicity in vitro and in vivo. Ann Rheum Dis (2010) 0.87
A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF. Hum Mol Genet (2011) 0.86
Adoptive transfer of IL-10-secreting CD4+CD49b+ regulatory T cells suppresses ongoing arthritis. J Autoimmun (2009) 0.86
Musculoskeletal disease burden of hereditary hemochromatosis. Arthritis Rheum (2010) 0.85
Synovial immunopathology in haemochromatosis arthropathy. Ann Rheum Dis (2009) 0.84
PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J (2009) 0.84
Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis Rheum (2010) 0.83
Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo. J Cell Mol Med (2009) 0.83
HFE-related hemochromatosis: an update for the rheumatologist. Curr Rheumatol Rep (2014) 0.82
Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum (2008) 0.81
Altered bone material properties in HLA-B27 rats include reduced mineral to matrix ratio and altered collagen cross-links. J Bone Miner Res (2014) 0.81
Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology (2011) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Role of NOD1 polymorphism in susceptibility and clinical progression of rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.80
Homocysteine induces serum amyloid A3 in osteoblasts via unlocking RGD-motifs in collagen. FASEB J (2012) 0.80
Mitogen-activated protein kinase 2 regulates physiological and pathological bone turnover. J Bone Miner Res (2013) 0.80
Idiopathic hand osteoarthritis vs haemochromatosis arthropathy--a clinical, functional and radiographic study. Rheumatology (Oxford) (2013) 0.80
Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheum (2011) 0.79
JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Arthritis Rheum (2012) 0.79
Hereditary hemochromatosis as a risk factor for joint replacement surgery. Am J Med (2010) 0.79
Decreased lymphatic vessel counts in patients with systemic sclerosis: association with fingertip ulcers. Arthritis Rheum (2010) 0.79
Risk prediction for severe osteoarthritis. Ann Rheum Dis (2010) 0.78
Acetylsalicylic acid, diclofenac, and lornoxicam, but not rofecoxib, affect platelet CD 62 expression. Anesth Analg (2004) 0.78
Oropharyngeal tularemia--a differential diagnosis of tonsillopharyngitis and cervical lymphadenitis. Wien Klin Wochenschr (2010) 0.78
VCAM-1 serum levels are associated with arthropathy in hereditary haemochromatosis. Ann Rheum Dis (2013) 0.77
Influence of antiTNF-alpha antibody treatment on fracture healing under chronic inflammation. BMC Musculoskelet Disord (2014) 0.77
[Austrian 3e-recommendations for diagnosis and management of gout 2013]. Wien Klin Wochenschr (2013) 0.77
Daily functioning and health status in patients with hand osteoarthritis: Fewer differences between women and men than expected. Wien Klin Wochenschr (2011) 0.77
Premature osteoarthritis as presenting sign of type II collagenopathy: a case report and literature review. Semin Arthritis Rheum (2012) 0.77
Sneaking-ligand fusion proteins attenuate serum transfer arthritis by endothelium-targeted NF-κB inhibition. Methods Mol Biol (2015) 0.77
IgG4-related disease. N Engl J Med (2012) 0.76
Coping strategies and depressiveness in primary systemic vasculitis--what is their impact on health-related quality of life? Rheumatology (Oxford) (2013) 0.76
Deletion of the receptor tyrosine kinase Tyro3 inhibits synovial hyperplasia and bone damage in arthritis. Ann Rheum Dis (2013) 0.75
The mitogen-activated protein kinase p38α regulates tubular damage in murine anti-glomerular basement membrane nephritis. PLoS One (2013) 0.75